Literature DB >> 21308492

Importance of a multidisciplinary approach for the treatment of Barrett's esophagus.

Carlo V Feo1, Marco G Patti.   

Abstract

Barrett's esophagus is a consequence of gastroesophageal reflux disease. Today, it is the most common cause of esophageal adenocarcinoma. Cancer is usually the end results of a cascade of events whereby metaplasia changes into low- and high-grade dysplasia and eventually cancer. Today, we have the unique opportunity to block this cascade and avoid the development of esophageal cancer. A multidisciplinary approach with a team composed of radiologists, gastroenterologists, pathologists, and surgeons allows individualization of care and the best results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21308492     DOI: 10.1007/s13304-011-0049-8

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  37 in total

1.  Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.

Authors:  M F Vela; L Camacho-Lobato; R Srinivasan; R Tutuian; P O Katz; D O Castell
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

2.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

3.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

4.  Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology.

Authors:  Anand P Tamhankar; Jeffrey H Peters; Giussepe Portale; Chih-Cheng Hsieh; Jeffrey A Hagen; Cedric G Bremner; Tom R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-11       Impact factor: 3.452

5.  Symptoms with acid and nonacid reflux may be produced by different mechanisms.

Authors:  A Agrawal; J Roberts; N Sharma; R Tutuian; M Vela; D O Castell
Journal:  Dis Esophagus       Date:  2009-02-13       Impact factor: 3.429

6.  Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy.

Authors:  Arjun Pennathur; Andrew Farkas; Alyssa M Krasinskas; Peter F Ferson; William E Gooding; Michael K Gibson; Matthew J Schuchert; Rodney J Landreneau; James D Luketich
Journal:  Ann Thorac Surg       Date:  2009-04       Impact factor: 4.330

7.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

8.  Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?

Authors:  J Tack; G Koek; I Demedts; D Sifrim; J Janssens
Journal:  Am J Gastroenterol       Date:  2004-06       Impact factor: 10.864

9.  Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus.

Authors:  D A Katzka; D O Castell
Journal:  Am J Gastroenterol       Date:  1994-07       Impact factor: 10.864

10.  Gastroesophageal reflux disease and obesity. Pathophysiology and implications for treatment.

Authors:  Fernando A M Herbella; Matthew P Sweet; Pietro Tedesco; Ian Nipomnick; Marco G Patti
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.